OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models

被引：0
|
作者：
Li, Wan-Fen
Chiang, Ming-Feng
Weng, Hao-Cheng
Yang, Jhih-Jie
Wu, Hsin-Shan
Lin, Chun-Jung
Chiu, Ping-Tzu
Lai, Ming-Tain
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1893
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor
    Zhong, Helen
    Xiong, Yan
    Huang, Han
    Pan, Yuming
    Cao, Lijin
    Liu, Shen
    Wang, Na
    Sun, Bing
    Liu, Dingguo
    Yuan, Wei
    Fang, Jan
    Bao, Haifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas
    Wang, Rong
    Li, Liang
    Zhang, Shenghua
    Li, Yi
    Wang, Xiaofei
    Miao, Qingfang
    Zhen, Yongsu
    MOLECULAR ONCOLOGY, 2018, 12 (03) : 339 - 355
  • [43] EFFICACY AND ADDITIONAL MECHANISM OF ACTION OF SACITUZUMAB GOVITECAN, A TROP-2 DIRECTED ANTIBODY-DRUG CONJUGATE, IN PRECLINICAL MODELS OF NON-MUSCLE INVASIVE BLADDER CANCER
    Chou, Chih-Chien
    Kornyeyev, Dmytro
    Yang, Becky
    Orf, Jessica
    Sun, Hai-Ling
    Dave, Rutwij
    Lai, Yurong
    Papalia, Giuseppe
    Cardillo, Thomas
    Scholler, Nathalie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1262 - A1262
  • [44] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
    Goldenberg, David M.
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Rossi, Edmund A.
    Sharkey, Robert M.
    ONCOTARGET, 2015, 6 (26) : 22496 - 22512
  • [45] Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses
    Dong, Yijun
    Zhang, Zongliang
    Luan, Siyuan
    Zheng, Meijun
    Wang, Zeng
    Chen, Yongdong
    Chen, Xiaoting
    Tong, Aiping
    Yang, Hui
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (10)
  • [46] A novel pegylated bispecific antibody-drug conjugate (P-BsADC) targeting Her2+cancers with improved efficacy and therapeutic window
    Wen, Yu
    Yin, Shuqiang
    Lyu, Weidong
    Lei, Yang
    Zhuo, Qiudong
    Wu, Zibin
    Sun, Bin
    Tan, Shuangyu
    Jiang, Lidong
    Zhang, Teng
    Gao, Bo
    Xu, Rui
    Li, Yong
    Zheng, Liling
    Liu, Shumin
    Wu, David
    CANCER RESEARCH, 2023, 83 (07)
  • [47] IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
    Kovtun, Yelena
    Noordhuis, Paul
    Whiteman, Kathleen R.
    Watkins, Krystal
    Jones, Gregory E.
    Harvey, Lauren
    Lai, Katharine C.
    Portwood, Scott
    Adams, Sharlene
    Sloss, Callum M.
    Schuurhuis, Gerrit Jan
    Ossenkoppele, Gert
    Wang, Eunice S.
    Pinkas, Jan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (06) : 1271 - 1279
  • [48] DB-1310, a novel Her3 targeting antibody-drug conjugate, exhibits therapeutic efficacy for solid tumors
    Li, Xi
    Yao, Jun
    Qu, Chen
    Lan, Luo
    Li, Bing
    Zhang, Yu
    Shi, Rong
    Hua, Haiqing
    Qiu, Yang
    CANCER RESEARCH, 2023, 83 (07)
  • [49] Novel Globo H targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types
    Yang, Ming-Chen
    Chen, Yu-Jung
    Shia, Chi-Sheng
    Chang, Hui-Wen
    Li, Wan-Fen
    Yu, Cheng-Der Tony
    Chen, I-Ju
    CANCER RESEARCH, 2019, 79 (13)
  • [50] SYD985, a novel HER2-targeting antibody-drug conjugate in preclinical models for USC, both in vitro and in vivo.
    Black, Jonathan
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Bonazzoli, Elena
    Schwab, Carlton
    English, Diana Peta-gay
    Goedings, Peter J.
    Beusker, Patrick
    van der Lee, Miranda
    Timmers, Marco
    Dokter, Wim
    Schwartz, Peter E.
    Santin, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345